How to use Technologies offered
A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.
Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.
Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.
Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.
Liposomal Clodronate as a Therapy for Auto-immune Hemolytic Anemia
National Jewish Health clinical and research institution
This invention is using liposomal clodronate as a therapy for auto-immune hemolytic anemia.
- Therapy for auto-immune hemolytic anemia
- The therapy is applicable to both humans and companion animals
Advantages of Invention
- The method is less invasive than surgery (splenectomy)
- Decrease use of steroids
- Decrease side effects
State of Development
- The efficacy of this therapy has been demonstrated by some strong in vivo data obtained in mice.
- Using a mouse model in which animals were given anti red blood cell antibodies, treatment with liposomal clodronate substantially decreased red blood cell destruction.
- In addition, this effect was detected within hours and lasted at least a week.
Further R&D Required
Additional in vivo studies with other animal models.
Available for licensing.
U.S. Patent # 7,090,865
- Mike Jordan, MD, Philippa Marrack, PhD and John Kappler, Ph
Jordan et al. (2003) Blood: 101(2): 594-601
Mathes et al. (2006) Exp Hemat; 34:1393-1402
To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login
Please click here to log in to view the complete profile.